ABBOTT LABORATORIES

Shareholders of Abbott Laboratories

Abbott Laboratories is a widely held public company listed on the New York Stock Exchange (ticker: ABT). As with most large-cap U.S. issuers, it does not have a small, named group of private shareholders; instead its shares are held by a broad public shareholder base, with the largest positions disclosed by institutional asset managers required to report holdings above five percent of outstanding common stock under SEC Schedule 13G rules. According to Abbott’s 2026 definitive proxy statement, filed with the SEC on March 13, 2026 based on a February 25, 2026 record date, only two holders were known to the company to beneficially own more than five percent of outstanding shares: The Vanguard Group, Inc., reporting approximately 174,894,079 shares (about 10.05 percent), and BlackRock, Inc., reporting approximately 134,061,311 shares (about 7.7 percent). Both are asset-management complexes reporting aggregate holdings across numerous investment funds and client accounts, rather than a single controlling beneficial owner.

Data availability

Disclosure of Abbott’s shareholder base is major shareholders only: U.S. securities law requires public disclosure only of holders exceeding the five-percent threshold, reported via Schedule 13G/13D filings and summarized annually in the company’s proxy statement. No individual or entity has been identified as an ultimate beneficial owner of Abbott Laboratories for control purposes; the disclosed five-percent holders report their positions in a fiduciary, asset-management capacity on behalf of underlying fund investors, not as concentrated personal or corporate ownership.

Sources

• Abbott Laboratories, Definitive Proxy Statement (Schedule DEF 14A), filed with the U.S. Securities and Exchange Commission, March 13, 2026 (record date February 25, 2026); retrieved September 11, 2026.

Directors and officers of Abbott Laboratories

Two categories of officer information are available for Abbott Laboratories. A Statement of Information filed with the California Secretary of State, reflecting the company’s registration to transact business in California, discloses a limited officer set, typically a chief executive officer, a chief financial officer, one director and the company’s agent for service of process, currently CT Corporation System (330 N Brand Blvd, Glendale, California). That registry filing on record lists Miles D. White as President and Chief Executive Officer, a role he left in 2020, indicating the underlying filing is outdated and does not reflect Abbott’s current leadership. Abbott’s more current SEC filings and its own investor-relations disclosures show that Robert B. Ford has served as Chief Executive Officer since March 31, 2020 and also holds the title of Chairman of the Board. Philip P. Boudreau serves as Executive Vice President, Finance and Chief Financial Officer, and Elizabeth C. Cushman serves as Executive Vice President, General Counsel and Secretary. Other senior officers named in Abbott’s 2026 proxy statement include Lisa D. Earnhardt (Group President, Medical Devices), Daniel G. Salvadori (Group President, Established Pharmaceuticals and Nutritional Products) and Christopher J. Scoggins (Diabetes Care). Abbott’s SEC disclosures do not report the nationality or country of residence of its executive officers.

Recent officer changes

• Robert B. Ford succeeded Miles D. White as Chief Executive Officer effective March 31, 2020, and has also served as Chairman of the Board (Abbott Laboratories press release, November 13, 2019, announcing the succession effective March 31, 2020).
• Philip P. Boudreau was appointed Chief Financial Officer effective September 1, 2023, and was later named Executive Vice President, Finance and Chief Financial Officer in 2024.
• Elizabeth C. Cushman was appointed Executive Vice President, General Counsel and Secretary in June 2025, succeeding Hubert L. Allen.

Data availability

Officer information for Abbott Laboratories is partial and mixed-vintage: the California Statement of Information on file discloses only a handful of roles as of its last filing date and has not been updated to reflect leadership changes since 2020, while SEC proxy-statement disclosures provide current executive officer names and titles but not nationality, country of residence, or appointment dates for every officer. Nationality and residence are not disclosed in either source and should not be inferred from names or business addresses.

Sources

• Abbott Laboratories, Definitive Proxy Statement (Schedule DEF 14A), filed with the SEC, March 13, 2026.
• Abbott Laboratories, “Abbott Announces Robert B. Ford to Succeed Miles D. White as Chief Executive Officer on March 31, 2020,” company press release, November 13, 2019.
• Abbott Laboratories corporate website, executive team biographies (Elizabeth Cushman, Phil Boudreau), retrieved September 11, 2026.
• California Secretary of State, bizfile Online, Statement of Information on file for Abbott Laboratories.

Group structure of Abbott Laboratories

Abbott Laboratories is an independent, publicly traded company and the ultimate parent of its own corporate group; it has no immediate or ultimate parent company above it. The group’s verified structure, consistent with the subsidiaries disclosed in Abbott’s most recent Form 10-K (Exhibit 21, List of Subsidiaries, filed with the SEC in February 2026), comprises approximately 306 identified group entities incorporated across 65 countries, organized beneath roughly 31 direct top-tier holding or operating subsidiaries. Exact ownership percentages for individual subsidiaries are not disclosed in Exhibit 21 filings, which list significant subsidiaries without stating the percentage interest held. The structure includes long-standing operating subsidiaries such as Abbott Vascular, Inc. and St. Jude Medical, LLC, regional holding companies in Luxembourg, the Netherlands and Bermuda, and subsidiaries added through recent acquisitions.

Verified corporate relationships

Recent structural changes

• Acquisition: Abbott completed the approximately 21 billion US dollar acquisition of Exact Sciences Corporation on March 23, 2026, following stockholder approval, adding Exact Sciences and its subsidiaries to Abbott’s group.
• Acquisition: Abbott completed the approximately 890 million US dollar acquisition of Cardiovascular Systems, Inc. on April 27, 2023.
• Historical acquisition: Abbott’s group includes entities acquired through its 2014 acquisition of CFR Pharmaceuticals, including Laboratorio Franco Colombiano Lafrancol S.A.S. and related Latin American operating companies.

Data availability

Corporate-linkage information for Abbott Laboratories is assessed as partial: the group listing reflects significant subsidiaries as disclosed in Exhibit 21 of Abbott’s Form 10-K, an official SEC filing, but Exhibit 21 does not report ownership percentages and, under SEC rules, need not list every subsidiary, so smaller or newly formed entities may be omitted. The relationships listed above have been cross-checked against Abbott’s public acquisition announcements or the entities’ registered names and jurisdictions.

Sources

• Abbott Laboratories, Form 10-K for fiscal year ended December 31, 2025, Exhibit 21 (List of Subsidiaries), filed with the SEC, February 2026.
• Abbott Laboratories and press coverage of the completed acquisition of Exact Sciences Corporation, March 2026.
• Abbott Laboratories, “Abbott Completes Acquisition of Cardiovascular Systems, Inc.,” press release, April 27, 2023.